Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
Age
50–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Between 50 and 90 years of age
Participants with diagnosis of macular neovascularization secondary to age-related macular degeneration (nAMD)
Study eye with best corrected visual acuity (BCVA) ETDRS Snellen equivalent for dose escalation (Part I) between 20/32 and 20/400 and for expansion (Part II) between 20/25 and 20/200
Current or previous use of anti-vascular endothelial growth factor (VEGF) treatment in the study eye
Demonstrated a response to anti-VEGF treatment
You may not be if
Any condition in the study eye that may prevent visual acuity improvement or interfere with ocular safety or efficacy assessments
History of active ocular infection in the study eye in 6 months prior to screening
Active uncontrolled glaucoma in the study eye
History of uveitis in either eye
Current use of ocular corticosteroids in the study eye
Previous gene therapy
Any significant poorly controlled illness that would preclude study compliance and follow up
The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
